



Annual General Meeting
27 November 2024



A transformative year of clinical and commercial success

Australian Financial Year

Q2 2023/24

ASX listing

Clinical data
presented at
WMSM Dubai

Q3 2023/24

Manufacturing
validation
completed

Clinical study
recruitment
commenced

Study recruitment
and dosing
completed

Q4 2023/24

Positive clinical
study results

470% faster
absorption
demonstrated

Q1 2024/25

Global partnership
with Aptar Pharma

TGA Special Access
Scheme
commenced

TGA Authorised
Prescriber Scheme
launched

Q2 2024/25

Final clinical study
results confirmed

Strategic joint
venture for
telehealth platform

Investment Highlights

LTR Pharma positioned in a clear gap in the market



Expedited path to market

Repurposed drugs with novel delivery methods can reach the market in the US and Australia quickly



Compelling pivotal pharmacokinetic study data

470% faster absorption than oral tablets



Blockbuster market with issues

Existing PDE5 inhibitors have a high discontinuation rate due to poor efficacy and side effects



Blue chip partners

Aptar Pharma: Strategic Co-development partner - Nasdaq listed;
Mayne Pharma: Commercial manufacturing partner (CMO) - ASX listed



Multiple upcoming milestones

Expanding product portfolio
Manufacturing Scale up
Online Prescribing
Regulatory studies / meetings
Potential partnerships/licensing

Understanding the Market Need

A significant healthcare challenge affecting relationships and quality of life



50% Stop purchasing PDE5 tablets¹



60% Of men over 45 experience ED²




Growing prevalence with age impacts quality of life

Physical causes

- ▶ Heart Health
- ▶ Hormone Balance
- ▶ Metabolic Health
- ▶ Medical Treatments
- ▶ Hair loss
- ▶ Weight loss
- ▶ Antidepressants

Psychological Impact

- ▶ Relationship problems
- ▶ Mental Wellbeing
- ▶ Day to day stress



Prevalence of ED with individuals with cardiovascular risk factors, hypertension and diabetes, is reported as high as 50%

Global Market Need


ED can impact physical and psychological health

Global ~322m men by 2025



Estimated Market size

Forecast to be US\$6.0B market by 2028



Online sales expansion

Majority of ED medication is now sold through online channels


Current treatments

Gold standard are PDE5 inhibitor tablets which have several drawbacks


Phosphodiesterase-5 (PDE5) inhibitors are first-line treatments

Product	Main Brand(s)	Time before sexual activity for dose	Approval Date (US)	Generic availability
Sildenafil	Viagra	1 hour+	1998	Yes
Tadalafil	Cialis	1 hour+	2003	Yes
Vardenafil	Levitra, Staxyn	1 hour+	2003	Yes
Avanafil	Stendra	30 minutes+	2012	No
SPONTAN		12 mins	TGA early access	No


Issues with PDE5 inhibitor tablets



Does not work for 30-35% of patients



Long response time of 1 hour + affects spontaneity



Adverse reactions in up to 35% of patients

= High discontinuation rate

SPONTAN® The Fast-Acting Solution

Transforming ED treatment with speed and confidence



Speed Matters

Peak concentration in as little as 9 mins, 470% faster than oral tablets
Average onset: 12 mins vs 56 mins



Less is More

Half the dose
Similar effectiveness
Better delivery consistency



Safety

Validated safety profile
No severe events
Clinically proven

Healthcare Professional Insight


*Patients can respond in **as little as 5 minutes**, well before peak concentration is reached*.*

*Based on healthcare professional feedback

Time to peak concentration (minutes)

Tablets

SPONTAN



Making headlines – all eyes on LTP

LTR Pharma engaged positively with all tiers of the media in FY24, including quality, regular coverage in industry, business, health and top tier mediums.

Whilst a high volume of headlines focused on the Company's outstanding share price growth, the story also attracted coverage in health-focused consumer mediums including Men's Health, Body + Soul, state and national newspapers, and more. These stories were initiated in partnership with leading key opinion leader, Professor Eric Chung, and clinical practitioner and advocate, Melissa Hadley Barrett, and the Company's management team.

LTR gets the rise on Viagra

Is a small Brisbane drug company about to make it big in the multibillion-dollar erectile dysfunction (ED) market?

LTR Pharma listed on the stock market this week after raising \$7m to accelerate the commercial development of its intranasal spray treatment called SPONTAN.

Viagra revolutionised the treatment of erectile dysfunction a quarter of a century ago and provided millions of men the possibility of enjoying a functional sex life.

But Viagra and its variants can take a long time to work, and affect spontaneity. Experts say the effect of the drug also depends on how your body metabolises medication.

LTR Pharma chair **Lee Rodne** says SPONTAN has an effect in as little as 10 minutes, with the nasal delivery bypassing the digestive system and going straight into the bloodstream. "The desire for greater control, timing and spontaneity in the enjoyment of sexual experiences is of paramount importance," says Rodne (illustrated).

"Men get very upset with Viagra when it doesn't work and half stop purchasing it. "It is a big problem when you consider 60 per cent of men have ED issues once they reach 45."

The global market for ED treatments is forecast to grow from \$US3.6bn (\$5.4bn) in 2021 to \$US5.9bn (\$8.8bn) by the end of 2028, and Rodne sees the little blue pills being

CITY BEAT with **Glen Norris**

eventually replaced by nasal sprays. The company has already successfully conducted phase one clinical trials with the aim of receiving marketing approval from US Food and Drug Administration.

He says Vardenafil, the active ingredient in SPONTAN, has a proven track record as an oral medicine but delivering it as a spray was complex, and drug giants such as Pfizer had tried and never managed to make it work.

Rodne, who used to work at **Andrew "Twiggy" Forrest's** Allied Medical, said SPONTAN could available in Australia by the middle of next



year and in the US in 2025. The shares were trading at 27c on Thursday compared to an opening price of 35c on Monday.

SCHOOLS' IN St Paul's School at Bald Hills has proven an important incubator for politicians of all types. The private school on Brisbane's outer north can now lay claim to being the alma mater of both premier-in-waiting **Steven Miles** and federal Opposition Leader **Peter Dutton**.

City Beat spies tell us the two leaders weren't at the school at the same time – Dutton being a few years older than Miles – so they weren't part of the same school debating team. Although that may have been a team torn by different internal views if they were together.



LTR Pharma, AFT Pharmaceuticals Make Major Strides in US Healthcare Market

LTR Pharma completes manufacturing validation for SPONTAN, an ED treatment. AFT Pharma's Malignant enters the US market. Allerga seeks buyers for its IP.

Subscribe to our Newsletter!

Don't panic as markets rise. Get ready for the final str. Know your super mix P57

WA patients become first in the world to access a nasal spray treatment for erectile dysfunction

Revolutionary Sexual Health Clinic founder **Melissa Hadley Barrett** says the new treatment will be welcomed by many.

Sexual Health Clinic founder Melissa Hadley Barrett

A TREATMENT ON THE UP

You can have it in a much lower dose which means the side effect profile should be a lot better.

Sexual Health Clinic founder Melissa Hadley Barrett



Who is LTR Pharma and what do you do?
Lee Rodne
Executive Chairman

Revolutionary Nasal Spray for Erectile Dysfunction: SPONTAN® Clinical Trial Begins

LTR Pharma initiates a clinical trial for SPONTAN®, an innovative nasal spray to treat erectile dysfunction. The fast-acting solution aims to redefine ED treatment and enhance the quality of life for many.

BNN Correspondents
18 Feb 2024 20:30 EST
Updated On 18 Feb 2024 20:36 EST

Follow Us

Revolutionary Nasal Spray for Erectile Dysfunction: SPONTAN® Clinical Trial Begins

In a groundbreaking move that could revolutionize the treatment of erectile dysfunction (ED), LTR Pharma has announced the initiation of a clinical trial for SPONTAN®, an innovative nasal spray designed to offer a fast-acting solution for men grappling with this sensitive condition. Set against the backdrop

THE AUSTRALIAN BUSINESS REVIEW

Monday, February 5, 2024 Today's Paper Mind Games

HOME THE NATION WORLD BUSINESS COMMENTARY SPORT ARTS ALL

On the rise: Erectile dysfunction nasal spray inventor LTR Pharma firms for ASX, market disruption

By **BOB BADMAN**

STOCKHEAD
KHAM NOVEMBER 30, 2023

Who, there you are? Picture: Getty Images

Spontaneity can play a large part in intimacy. But when that spontaneity hinges on the timing and mechanism of a slow-acting oral pill, things can flop.


LTR Pharma – which aims to list on the ASX this year – believes it's cracked the code with a revolutionary erectile dysfunction nasal spray called Spontan.

It's well established that spontaneity is a highly conducive ingredient when it appears a little romance could be on the cards. Or the table. Maybe a sturdy card table. Okay, a bed would be better.

For the latest health news, sign up here for free Stockhead daily newsletters

Company History

Progressed company substantially derisking the proposition



Board of Directors

Seasoned leadership driving innovation and growth in healthcare



LEE RODNE

(Executive Chairman)

- ▲ 25 years in healthcare and tech sectors in both public ASX and private enterprises.
- ▲ Led a healthcare spin out from ASX Fortescue Metals Group (Allied Medical, Admedus Ltd)
- ▲ Worked with Professor Ian Frazer on advancing therapeutic vaccines into clinical studies

Track record of commercializing medical devices in Australia, North America, Europe and Asia with significant experience in Nasal Spray product sales.

MS MAJA MCGUIRE

(Independent Non-Executive Director)

- ▲ 15 years of experience providing corporate and compliance advice to ASX-listed public companies as an Australian-qualified lawyer.
- ▲ This includes working with listed companies as a non-executive director, general counsel, company secretary and in private practice.
- ▲ Current Non-Executive Chair of ASX listed TechGen Metals (ASX:TG1), non-executive director of Kuniko (ASX:KNI) and non-executive director of Indiana Resources Limited (ASX:IDA).

DR JULIAN CHICK

(Independent Non-Executive Director)

- ▲ 20 years experience in senior management and board positions, including in ASX-listed companies Avexa Ltd, Admedus Ltd and current Chair of Cann Group Ltd (ASX:CAN).
- ▲ Over 8 years of experience in investment banking and reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.

Global Team, Strategic US Presence

Experienced leadership across key markets

Executive Chairman | Lee Rodne

25 years in healthcare and tech sectors in both public ASX and private enterprises.

Chief Operating Officer | Peter McLennan

17 years experience in investment banking, investor relations and operations.

Chief Finance Officer | Jacques Shipper

14 years experience in Finance, Commercial Management and Controller roles.

Medical Liaison Officer | Chris Rosewarne

Experienced pharmaceutical and medical device industry leader with over 20 years experience.

Vice President – Commercial | Danny Zanardo

25 years commercial experience in the Australian and global healthcare sectors across pharmaceuticals and medical devices.

Chief Medical Officer | Prof Geoffrey Strange

20 years experience in Pharmaceutical and medical industries as a Senior Executive and Medical Researcher.

General Manager & Business Development US | Tom Riester

25 years experience in sales and management in digital health, medical device and precision medicine.

Vice President – US Sales & Marketing | Mike Sweeting

30 years in the Pharmaceutical industry in US commercial sales and Market Access.

Vice President Operations & Clinical Development | Dr Monil Shah

20 years of Pharmaceutical and biotechnology industry experience in drug development.

Vice President, Global Regulatory Affairs | Kip Vought

25 years across global markets - Senior Pharmaceutical R&D and regulatory executive.

US TEAM

Upcoming Milestones

Multiple value inflection points in the year ahead



**Expanding
product portfolio**



**Manufacturing
scale up**



**Online
prescribing**



**Regulatory
studies
& meetings**



**Potential
partnerships &
licensing**